Search alternatives:
026 decrease » _ decrease (Expand Search), nn decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
026 decrease » _ decrease (Expand Search), nn decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
-
81
-
82
-
83
-
84
-
85
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
86
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
87
-
88
Description of the cohort (N = 118 patients).
Published 2023“…An HLA-G plasma level ≤ 50 ng/ml on day 8 after LT was significantly associated with a higher rejection risk. …”
-
89
-
90
-
91
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
Published 2024“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
-
92
-
93
-
94
Antibodies used for flow cytometry experiments.
Published 2023“…RA was devoid of serious side effects, and within 24 hours from the start of infusion was associated with increased oxygen saturation (93.8 ± 0.58 vs 96.6 ± 1.08%, P<0.05), decreased D-dimer (754 ± 17 vs 518 ± 98 ng/ml, P<0.05), and a trend toward decreased CRP (3.80 ± 1.40 vs 1.98 ± 0.74 mg/dL, P = 0.075). …”
-
95
Subject flow diagram.
Published 2023“…RA was devoid of serious side effects, and within 24 hours from the start of infusion was associated with increased oxygen saturation (93.8 ± 0.58 vs 96.6 ± 1.08%, P<0.05), decreased D-dimer (754 ± 17 vs 518 ± 98 ng/ml, P<0.05), and a trend toward decreased CRP (3.80 ± 1.40 vs 1.98 ± 0.74 mg/dL, P = 0.075). …”
-
96
-
97
-
98
-
99
-
100
The primers related to FAM50A.
Published 2025“…Knockdown of FAM50A decreased cell proliferation ability, the proportion of EdU positive cells, and the number of CRC cell colonies, whereas overexpressing FAM50A promoted proliferative phenotypes. …”